{"id":"W4360608257","doi":"10.1200/jco.22.01649","title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":319,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Abiraterone acetate; Medicine; Prostate cancer; Enzalutamide; Cohort; Placebo; Hazard ratio; Internal medicine; Prednisone; Oncology; Clinical endpoint; Urology; Progression-free survival; Androgen deprivation therapy; Androgen receptor; Cancer; Chemotherapy; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025867,0.0001048719,0.0009469683,0.000145355,0.00006408044,0.00001693269,0.00006303902,0.000103282,0.00004602591],"category_scores_gemma":[0.0008796965,0.00006448111,0.0002072878,0.0001860839,0.0002110673,0.000103015,0.00002766956,0.0003648335,0.00000993173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009670948,"about_ca_system_score_gemma":0.001704133,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002404793,"about_ca_topic_score_gemma":0.00008096982,"domain_scores_codex":[0.9978606,0.000157457,0.001284315,0.0001625594,0.0002562234,0.0002788452],"domain_scores_gemma":[0.997283,0.001194092,0.0006442029,0.0000907738,0.0004672779,0.0003206754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.06785408,0.001988784,0.07667806,0.001013614,0.004141139,0.003795408,0.001456437,0.0001251142,0.02028451,0.0004405582,0.05760243,0.7646199],"study_design_scores_gemma":[0.07826763,0.0575752,0.5324579,0.0005181925,0.002351242,0.0004197551,0.001268921,0.001206166,0.002920762,0.00543464,0.3172293,0.0003503123],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9713169,0.001840265,0.00003982451,0.02530276,0.0006539192,0.0005809657,0.00003776594,0.00001404694,0.0002135108],"genre_scores_gemma":[0.9788234,0.01021579,0.003604244,0.0008484481,0.0006614148,0.00008287623,0.00001883676,0.00002723768,0.005717766],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7642695,"threshold_uncertainty_score":0.3023058,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2899895319608854,"score_gpt":0.5543641495000348,"score_spread":0.2643746175391494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}